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We present a fundamental study into the self-assembly of (cyclic peptide)-polymer 
conjugates as a versatile supramolecular motif to engineer nanotubes with defined structure 
and dimensions, as characterised in solution using small angle neutron scattering (SANS). 
This work demonstrates the ability of the grafted polymer to stabilise and/or promote the 
formation of unaggregated nanotubes by the direct comparison to the unconjugated cyclic 
peptide precursor. This ideal case permitted a further study into the growth mechanism of 
self-assembling cyclic peptides, allowing an estimation of the cooperativity. Furthermore we 
show the dependency of the nanostructure on the polymer and peptide chemical functionality 
in solvent mixtures that vary in the ability to compete with the intermolecular associations 
between cyclic peptides and ability to solvate the polymer shell. 
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Nanotubes are attractive scaffolds for a variety of applications such as materials, 
electronics, sensors, catalysis, drug delivery and ion channels, owing to their anisotropic 
geometry, rigid structure and their internal pore.[1-6] While there are covalent-based routes to 
tubular nanostructures, notably, bottlebrush copolymers[7-9] and carbon nanotubes,[10] the 
performance of natural systems such as gramicidin A,[11,12] α-hemolysin,[13] and the tobacco 
mosaic virus,[14,15] which are capable of precise manufacturing of nanotubes as well as 
enabling dynamic/reversible properties, are highly inspiring incentives for taking a 
supramolecular approach. 
Self-assembly is a powerful route that has been used to realise synthetic structures 
with control on the nanometer length scale.[16] Pioneered in the 1990s, cyclic peptides (CPs) 
of alternating D and L amino acids adopt a conformation that promotes stacking between CP 
units by the formation of cylindrical β-sheets.[17,18] Many groups, including our own, have 
used self-assembling CPs as a guiding motif for nanotube structures. Self-assembling CPs are 
a highly versatile design platform[19] in which alterations to the CPs are reflected in the final 
cyclic peptide nanotube assembly; for example, the number of amino acids in the CP 
correlates to the diameter of the nanotube.[19] Since the earliest examples of self-assembling 
CPs, imaging techniques have shown the assemblies as very long and rigid structures,[17] yet 
controlling the length of the extended nanotube structures (i.e. beyond dimerisation) is not 
straightforward, requiring the self-assembly process to be tamed. However, in a recent 
example, Mizrahi et al. demonstrated length control through the use of a ‘layer-by-layer’-like 
approach, where the authors sequentially deposited positively and negatively charged CPs to 
obtain short nanotubes of precise lengths.[20] An interesting templating approach was 
proposed by Granja et al., stemming from their molecular dynamics study of CPs (α and γ 
residues), they suggest that the use of organochloride molecules in a highly hydrogen 
bonding competitive solvent (such as water) would promote the association of the CPs 
around the guest molecule (i.e. enveloping the molecule in the core of the nanotube) and 
promote dissociation of the CPs beyond the chain length of the organochloride molecule.[21] 
The conjugation of synthetic polymers to natural products, particularly biopolymers, 
is a simple and effective approach to combine functionalities which can be engineered for a 
multitude of applications.[22-24] Likewise the recent developments in covalent tethering 
synthetic polymers to self-assembling cyclic peptides[25-30] have further widened the 
possibilities by adding functionality for processing,[31,32] pH[33] or temperature[34,35] stimuli 
response, or for drug delivery.[36,37] Additionally the tethered polymers allow control over the 
nanotubular structure such as the diameter,[38,39] ordering and orientation,[40] promoting 
formation of macropores,[41] or to stabilise the otherwise dynamic exchange of CPs[39,42]. In 
the context of controlling the nanotube length, Biesalski et al. first suggested the use of 
increasing the polymer mass and graft density to tailor the length of the nanotubes by steric 
repulsion.[25] These authors then investigated the impact of the polymer molecular mass by 
using atomic force microscopy to characterise the surface absorbed nanostructure (after 
drying) which showed an increase in height and decrease in nanotube length as the polymer 
molar mass increased.[38] Recently we reported the first characterisation of (cyclic peptide)-
polymer assemblies in solution by the use of small angle neutron scattering (SANS), 
confirming their rigid rod structure and providing the dimensions of the assembly.[43] An 
interesting result of this study showed the impact of the grafted polymer length on the 
assembly structure in solution, revealing that the nanotube length depends on both steric 
hindrance and solvent accessibility to the peptide core, i.e. the increase of tethered polymer 
mass can promote the formation of tubes by shielding the CP core from a solvent that 
competes with the intermolecular H-bonding between CPs.[43] 
Here we directly compare the supramolecular structures formed by non-conjugated 
CPs and polymer-conjugated CPs in solution by SANS, and also examine the influence of the 
solvating media by varying the strength of competition for H-bonding sites and polymer 
solvation. These conjugates present an ideal system by which to study the self-assembly of 
cyclic peptides, providing insight to the growth mechanism including an estimation of the 
degree of cooperativity. Variations to the cyclic peptide residues with polar and non-polar 
side chains also enable a study of the impact of chemical functionality at the external 




Microwave-assisted copper(I) catalysed azide-alkyne cycloaddition (CuAAC) 
reactions were performed using a CEM Discover SP microwave reactor using 5 mL 
borosilicate microwave vessels. 
 
Synthesis 
Detailed synthetic methods can be found in the supplementary information. In brief: 
Fmoc-L-Lys(N3)-OH was prepared from Fmoc-L-Lys-OH using a diazotransfer reagent[44,45] 
in a method described in literature.[27] 4-(4,6-Dimethoxy-1,3,5-triazin)-4-
methylmorpholinium tetrafluoroborate (DMTMM.BF4) was prepared following literature 
procedures.[46] Linear octapeptides were synthesised by fluorenylmethyloxycarbonyl (Fmoc) 
solid phase peptide synthesis[47-49] using: 2-chlorotrityl chloride resin; Fmoc deprotection 
with piperidine/N,N-dimethylformamide (DMF) (1:4 v/v); amino acid coupling with 
HBTU/HATU, N,N-diisopropylethylamine (DIPEA), DMF; and cleaved from the resin with 
1,1,1,3,3,3-hexafluoroisopropanol (HFIP)/dichloromethane (DCM) (1:4 v/v). Cyclic peptides 
were synthesised by the head-to-tail coupling of linear peptides as described below. 
CP1. H2N(-L-Lys(N3)-D-Leu-L-Trp(Boc)-D-Leu)2-OH (0.41 g, 0.31 mmol) was 
dissolved in DMF (20 mL) with 5 min of sonication. The solution was purged with N2(g) at 
room temperature, then cooled with an ice/water bath. DMTMM.BF4 (0.12 g, 0.37 mmol) in 
DMF (5 mL) was purged with N2(g) and added dropwise to the linear peptide solution. The 
solution was brought to room temperature and stirred for 91 h under an atmosphere of N2(g). 
DMF was removed under reduced pressure. The residue was washed with ice-cold MeOH 
(4×20 mL) then dried under reduced pressure. Boc groups were removed by treatment with 
TFA/TIPS/H2O (18:1:1 v/v/v, 5 mL) for 2 h, then the mixture was triturated with ice-cold 
diethyl ether and washed twice with ice-cold diethyl ether to give CP1 as an off-white 
powder: 0.25 g, 71 % yield; 1H NMR (400 MHz, TFA-d) δ ppm: 8.11 (d, J = 8 Hz, 2H, 
2×Trp-CHaromatic), 7.66 (d, J = 8 Hz, 2H, 2×Trp-CHaromatic), 7.54 (s, 2H, 2×Trp-CHaromatic), 
7.26-7.42 (m, 4H, 4×Trp-CHaromatic), 5.21 (t, J = 8 Hz, 2H, 2×Trp-α-H), 4.60-4.85 (br m, 6H, 
4×Leu-α-H + 2×Lys(N3)-α-H), 3.00-3.40 (br m, 8H, 2×Lys(N3)-CH2-N3 + 2×Trp-α-CH2), 
0.50-2.00 (br m, 48H, 2×Lys(N3)-α-CH2-CH2-CH2 + 4×Leu-α-CH2-CH + 8×Leu-CH3); 
MALDI-FTICR MS m/z = 1156 (M+Na)+; ATR-FTIR νmax cm-1: 3270 (N-Hstr), 2093 (N3), 
1626 (C=Ostr). 
CP2. H2N(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2-OH (0.09 g, 0.08 mmol) was 
dissolved in DMF (73 mL) with 1 h of sonication at 40 °C. The solution was purged with 
N2(g). DMTMM.BF4 (0.03 g, 0.09 mmol) in DMF (3 mL) was purged with N2(g) and added 
dropwise to the linear peptide solution. The solution was stirred for 67 h at 40 °C under an 
atmosphere of N2(g). DMF was removed under reduced pressure. The residue was washed 
with MeOH precooled to -78 oC (dry-ice/acetone) (2×10 mL) then dried under reduced 
pressure to give CP2 as a white powder: 42 mg, 45 % yield; 1H NMR (400 MHz, TFA-d); 
1H NMR (400 MHz, TFA-d) δ ppm: 4.60-5.00 (m, 8H, 2×Lys(N3)-α-H + 2×Lys-α-H + 
4×Leu-α-H), 3.41 (t, J = 6 Hz, 4H, 2×Lys(N3)-CH2-N3), 3.20-3.34 (br m, 4H, Lys-CH2-NH2), 
1.25-2.12 (br m, 36H, 2×Lys(N3)-α-CH2-CH2-CH2 + 2×Lys-α-CH2-CH2-CH2 + 4×Leu-α-
CH2-CH), 0.91-1.11 (br m, J = 8 Hz, 24H, 8×Leu-CH3); ESI-LCQ MS m/z = 1240 (M+Na)+; 
ATR-FTIR νmax cm-1: 3270 (N-Hstr), 3037-2800 (C-Hstr), 2096 (N3), 1624 (C=Ostr). 
CP3. H2N(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2-OH (0.19 g, 0.15 mmol) was 
dissolved in DMF (142 mL) with 75 min of sonication at 40 °C. The solution was purged 
with N2(g). DMTMM.BF4 (0.06 g, 0.18 mmol) in DMF (20 mL) was purged with N2(g) and 
added dropwise to the linear peptide solution. The solution was stirred for 67 h at 40 °C 
under an atmosphere of N2(g). DMF was removed under reduced pressure. Boc groups were 
removed by treatment with TFA/thioanisole/TIPS/H2O (88:5:2:5vol, 20 mL) for 2 h, then the 
mixture was washed with acetic acid/diethyl ether precooled to -78 oC (dry-ice/acetone) 
(1:1 v/v, 2×40 mL), washed twice with diethyl ether precooled to -78 oC (dry-ice/acetone)  
(2×40 mL) and then dried under reduced pressure to give CP3 as a white powder: 63 mg, 
33 % yield; 1H NMR (400 MHz, TFA-d) δ ppm: 4.75-5.15 (m, 8H, 2×Lys(N3)-α-H + 2×Lys-
α-H + 4×Leu-α-H), 3.56 (t, J = 8 Hz, 4H, 2×Lys(N3)-CH2-N3), 3.33-3.50 (br m, 4H, Lys-
CH2-NH2), 1.40-2.26 (br m, 36H, 2×Lys(N3)-α-CH2-CH2-CH2 + 2×Lys-α-CH2-CH2-CH2 + 
4×Leu-α-CH2-CH), 1.17 (d, J = 8 Hz, 24H, 8×Leu-CH3); MALDI-FTICR MS m/z = 1068 
(M-2N2+Ag)+; ATR-FTIR νmax cm-1: 3273 (N-Hstr), 3006-2790 (C-Hstr), 2099 (N3), 1627 
(C=Ostr). 
CP-(NH3.CF3COO)2. H2N(-L-Lys(Boc)-D-Leu-L-Trp(Boc)-D-Leu)2-OH (1.00 g, 
0.67 mmol) was dissolved in DMF (115 mL) with 10 min of sonication. The solution was 
purged with N2(g) at room temperature, then cooled with an ice/water bath. DMTMM.BF4 
(0.26 g, 0.8 mmol) in DMF (15 mL) was purged with N2(g) and added dropwise to the linear 
peptide solution. The solution was brought to room temperature and stirred for 6 d under an 
atmosphere of N2(g). DMF was removed under reduced pressure. The residue was suspended 
and washed with ice/water-cold MeOH (3×20 mL) then dried under reduced pressure. 
Cyclo[(-L-Lys(Boc)-D-Leu-L-Trp(Boc)-D-Leu)2] (0.148 g, 0.099 mmol) was treated with 
TFA/TIPS/H2O (18:1:1 v/v/v, 5 mL) for 2 h, then the mixture was triturated with diethyl 
ether precooled to -78 oC (dry-ice/acetone)  and washed twice with diethyl ether precooled to 
-78 oC (dry-ice/acetone) to give cyclo[(-L-Lys-D-Leu-L-Trp-D-Leu)2] as an off-white powder: 
124 mg, 96 % yield; 1H NMR (400 MHz, TFA-d) δ ppm: 8.13 (d, J = 8 Hz, 2H, 2×Trp-
CHaromatic), 7.65 (d, J = 8 Hz, 2H, 2×Trp-CHaromatic), 7.55 (s, 2H, 2×Trp-CHaromatic), 7.26-7.42 
(m, 4H, 4×Trp-CHaromatic), 5.22 (t, J = 8 Hz, 2H, 2×Trp-α-H), 4.60-4.87 (m, 6H, 4×Leu-α-H + 
2×Lys-α-H), 3.04-3.37 (m, 8H, 2×Lys-CH2-N + 2×Trp-α-CH2), 0.55-2.00 (br m, 48H, 
2×Lys-α-CH2-CH2-CH2 + 4×Leu-α-CH2-CH + 8×Leu-CH3); ESI-ToF MS m/z = 1081.0 
(M+H)+; ATR-FTIR νmax cm-1: 3273 (N-Hstr), 1627 (C=Ostr). 
r-terminal alkyne RAFT agent (propynyl 2-propanoate)yl butyl trithiocarbonate 
(PPBTC) was prepared following a similar protocol to that described previously.[50] r-
terminal N-succinimidyl ester RAFT agent (NHS-PABTC) was prepared following a 
previously described  protocol.[35,41] Polymers with α-alkyne and α-NHS functional group 
were synthesised by RAFT polymerisation. 
 Poly(n-butyl acrylate) with an alkyne end group was synthesised by RAFT 
polymerisation: PPBTC (0.25 g, 0.9 mmol), BA (3.9 g, 31.5 mmol) and AIBN (0.015 g, 
0.09 mmol) was mixed and diluted to 40 % (w/w) with dioxane, cooled in an ice bath and 
purged with N2(g) for 15 min before stirring at 70 °C under an atmosphere of N2(g) until 79 % 
conversion determined by 1H NMR. The polymer was precipitated and washed with ice-cold 
water/MeOH (1:9) to yield pBA30 as a yellow viscous liquid: Mn (1H NMR) = 4200 g·mol-1; 
1H NMR (400 MHz, CDCl3) δ ppm: 4.78-4.88 (m, 1H, pBA-S-CH), 4.58-4.72 (m, 2H, 
PPBTCR-COO-CH2), 3.80-4.30 (m, 30×2H, pBA-COO-CH2), 3.34 (t, J = 6 Hz, 2H, S-CH2), 
0.70-2.60 (m, 311H,  PPBTCZ-CH2-CH2-CH3 + 30×pBA-CH2-CH2-CH3 + 30×pBAbackbone-
CH-CH2 + PPBTCR-CH3 + PPBTCR-C≡CH); SEC-DRI(DMF+LiBr): Mn = 3500 g·mol-1, Đ 
= 1.16. MALDI-ToF MS: (M+Na)+ observed; repeat unit m/z = 128, end group m/z = 276. 
Poly(n-butyl acrylate) with an N-succinimidyl ester end group was synthesised by 
RAFT polymerisation. NHS-PABTC (0.075 g, 0.22 mmol), BA (1.04 g, 7.8 mmol), ACVA 
(0.018 g, 0.0065 mmol) in dioxane (0.94 g) was purged with N2(g) for 15 min before stirring 
at 70 °C under an atmosphere of N2(g) until 94 % conversion determined by 1H NMR. The 
polymer was twice precipitated and washed with water/MeOH (1:9) precooled to -78 oC (dry-
ice/acetone) to yield pBA33 as a yellow viscous liquid: Mn (1H NMR) = 4600 g·mol-1; 
1H NMR (300 MHz, CDCl3) δ ppm: 4.76-4.89 (br t, 1H, pBA-S-CH), 3.86-4.20 (m, 33×2H, 
pBA-COO-CH2), 3.34 (t, J = 6 Hz, 2H, S-CH2), 2.67-2.89 (m, 5H, NHS-CH2-CH2- + R-CH-
COO), 0.66-2.67 (m, 339H, Z-CH2-CH2-CH3 + 33×pBA-CH2-CH2-CH3 + 33×pBAbackbone-
CH-CH2 + R-CH3); SEC-DRI(CHCl3+TEA): Mn = 4700 g·mol-1, Đ = 1.09. 
CP1-(pBA30)2 was synthesised following a previously described protocol.[29] CP1 
(40 mg, 0.035 mmol) was suspended in TFE (2 mL) by sonication for 10 min. PBA30 (0.31 g, 
0.074 mmol), sodium ascorbate (0.14 g, 0.71 mmol) and CuSO4.5H2O (0.037 g, 0.14 mmol) 
in DMF (3 mL) were added to the cyclic peptide solution, then the mixture was placed in a 
microwave reactor and irradiated (dynamic mode) at 100 °C for 15 min with a flow of N2(g) 
and delivering 200 W in the initial ramp. TFE and DMF were removed under reduced 
pressure. The crude product was dissolved in DCM and washed with an aqueous solution of  
EDTA (2×30 mL, 0.055 M, pH 8.5), then water (30 mL), and dried over MgSO4. After 
concentration in vacuo, CP1-(pBA30)2 was obtained as a brown film: 145 mg, 100 % 
conversion (ATR-FTIR); 1H NMR (300 MHz, TFA-d) δ ppm: 8.48 (s, 2H, 2×triazole-CH), 
7.60 (s, 2H, 2×Trp-CHaromatic), 7.34 (s, 2H, 2×Trp-CHaromatic), 7.02-7.26 (m, 6H, 6×Trp-
CHaromatic), 5.46 (s, 4H, 2×O-CH2-triazole), 5.18 (s, 2H, 2×Trp-α-H), 4.52-4.87 (m, 6H, 
4×Leu-α-H + 2×Lys-α-H), 4.24 (s, 64H, 32×pBA-O-CH2), 3.95 (s, 2H, PPBTCz-CH2), 1.71 
(s, 64H, 32×pBA- CH2), 1.42 (s, 64H, 32×pBA-CH2), 0.98 (s, 96H, 32×pBA-CH3), 0.73-0.89 
(m, 24H, 8×Leu-CH3), 0.45 (d, J = 10.15 Hz, 3H, PPBTCr-CH3), 0.15-0.22 (m, 3H, PPBTCz-
CH3); ATR-FTIR νmax cm-1: 3274 (N-Hstr), 3045-2750 (C-Hstr), 1728 (C=Op(BA)), 1625 
(C=OCP-str). 
CP2-(pBA30)2. CP2 (10 mg, 0.008 mmol), pBA30 (0.071 g, 0.017 mmol), sodium 
ascorbate (0.016 g, 0.081 mmol) and CuSO4.5H2O (0.009 g, 0.036 mmol) were suspended in 
DMF (3 mL), then the mixture was placed in a microwave reactor and irradiated (dynamic 
mode) at 100 °C for 15 min with a flow of N2(g) and delivering 200 W in the initial ramp. The 
DMF was removed under reduced pressure. In attempt to push the reaction to completion, a 
second microwave irradiation was performed after adding sodium ascorbate (0.016 g, 
0.081 mmol) and CuSO4.5H2O (0.009 g, 0.036 mmol) in DMF (3 mL). The crude product 
was dissolved in CHCl3 and washed with an aqueous solution of EDTA (2×30 mL, 0.055 M, 
pH 8.5), then water (30 mL), and dried over MgSO4. After concentration in vacuo, CP2-
(pBA30)2 was obtained as a dark brown film: 54 mg, < 100 % conversion (ATR-FTIR); ATR-
FTIR νmax cm-1: 3272 (N-Hstr), 3040-2800 (C-Hstr), 2098 (N3), 1729 (C=Op(BA)), 1624 
(C=OCP-str). 
CP2-(pBA30)1.5. CP2 (5 mg, 0.004 mmol), pBA30 (0.024 g, 0.006 mmol), sodium 
ascorbate (0.008 g, 0.040 mmol) and CuSO4.5H2O (0.005 g, 0.020 mmol) were suspended in 
DMF (2.5 mL), then the mixture was placed in a microwave reactor and irradiated (dynamic 
mode) at 100 °C for 15 min with a flow of N2(g) and delivering 200 W in the initial ramp. The 
DMF was removed under reduced pressure, then the crude product was dissolved in CHCl3 
and washed with an aqueous solution of EDTA (2×30 mL, 0.055 M, pH 8.5), then water (30 
mL), and dried over MgSO4. After concentration in vacuo, CP2-(pBA30)1.5 was obtained as a 
brown film: 20 mg, ≤ 100 % conversion (ATR-FTIR); ATR-FTIR νmax cm-1: 3270 (N-Hstr), 
3040-2800 (C-Hstr), 2097 (N3), 1732 (C=Op(BA)), 1625 (C=OCP-str). 
 CP3-(pBA30)2. CP3 (10 mg, 0.008 mmol), pBA30 (0.085 g, 0.021 mmol), sodium 
ascorbate (0.020 g, 0.098 mmol) and CuSO4.5H2O (0.010 g, 0.039 mmol) were suspended in 
DMF (2 mL) then the mixtrue was placed in a microwave reactor and irradiated (dynamic 
mode) at 100 °C for 15 min with a flow of N2(g) and delivering 200 W in the initial ramp. The 
DMF was removed under reduced pressure and the crude product was dissolved in DCM and 
washed with an aqueous solution of EDTA (2×30 mL, 0.055 M, pH 8.5), then water (30 mL), 
and dried over MgSO4. After concentration in vacuo, CP3-(pBA30)2 was obtained as a dark 
brown film: 52 mg, ≤ 100 % conversion (ATR-FTIR); ATR-FTIR νmax cm-1: 3279 (N-Hstr), 
3050-2800 (C-Hstr), 1733 (C=Op(BA)), 1631 (C=OCP-str). 
 CP3-(pBA30)1.5. CP3 (10 mg, 0.008 mmol), pBA30 (0.062 g, 0.015 mmol), sodium 
ascorbate (0.021 g, 0.11 mmol) and CuSO4.5H2O (0.011 g, 0.042 mmol) were suspended in 
DMF (2 mL), then the mixture was placed in a microwave reactor and irradiated (dynamic 
mode) at 100 °C for 15 min with a flow of N2(g) and delivering 200 W in the initial ramp. The 
DMF was removed under reduced pressure. The crude product was dissolved in DCM and 
washed with an aqueous solution of EDTA (2×30 mL, 0.055 M, pH 8.5), then water (30 mL), 
and dried over MgSO4. After concentration in vacuo, CP3-(pBA30)1.5 was obtained as a dark 
brown film: 49 mg, ≤ 100 % conversion (ATR-FTIR); ATR-FTIR νmax cm-1: 3280 (N-Hstr), 
3060-2800 (C-Hstr), 1733 (C=Op(BA)), 1631 (C=OCP-str). 
 CP-(pBA33)2 by NHS conjugation. Cyclo[(-L-Lys-D-Leu-L-Trp-D-Leu)2] (0.020 g, 
0.015 mmol), pBA33 (0.202 g, 0.044 mmol) and NMM (0.093 g, 0.092 mmol) were 
suspended in a mixture DMF/DMSO (1:3vol, 4 mL) and stirred for 4 days at room 
temperature. Solvents were removed with a stream of N2(g) and the product was redissolved in 
DCM, then precipitated into dry-ice/acetone-cold MeOH/H2O (9:1vol). The precipitate was 
redissolved in THF and purified by preparative size exclusion using a column of Bio-Beads 
S-X1. Gravity flow elution permitted isolation of conjugate in the form of self-assembled 
structures as detected by laser light scattering and analysed by SEC(DMF). Concentrated in 
vacuo, CP-(pBA33)2 was obtained as a yellow film: 9.7 mg, 100 % conversion (ATR-FTIR); 
Mp (SEC-DRI(DMF+NH4BF4)) = 6600 g.mol-1 (n.b. free polymer Mp 2900 g.mol-1); ATR-
FTIR νmax cm-1: 3276 (N-Hstr), 3040-2800 (C-Hstr), 1733 (C=Op(BA)), 1624 (C=OCP-str). 
 
Small angle neutron scattering (SANS) 
SANS measurements were performed on the NG3 beamline at the National Institute 
of Standards of Technology Center for Neutron Research in Gaithersburg, MD, USA. Raw 
data was corrected for detector sensitivity, background and empty cell scattering, and then 
converted to absolute scattered intensity (dS/dW cm-1) from the absolute neutron flux.[51] 
Incident neutrons had an average wavelength of 6 Å and wavelength resolution Δλ/λ = 0.124. 
Sample-to-detector distances (SDD) of 1.33 m and 8 m were used and the data combined for 
0.0057 Å-1 ≤ q ≤ 0.43 Å-1. For CP1-(pBA30)2 in THF-d8 (2 mM), SDD of 1.33 m, 8 m, and 
13.17 m were used and the data combined for 0.0030 Å-1 ≤ q ≤ 0.43 Å-1. Hellma cells (2 mm 
path length) were used for data acquisition. 
 
SANS sample preparation 
CP1-pBA30 (1 mM) samples in TFA-d/THF-d8 (1:9 v/v and 9:1 v/v) and TFA-
d/CDCl3 (1:9 v/v and 9:1 v/v) mixtures were prepared from mixing appropriate volumes of 
CP1-pBA30 (1 mM in TFA-d), CP1-pBA30 (1 mM in THF) and CP1-pBA30 (1 mM in 
CDCl3) then transferred to Hellma cells for data acquisition. An alternative sample 
preparation (as indicated in text), involving the solvent mixture TFA-d/THF-d8 (1:9 v/v), was 
prepared by dissolving CP1-pBA30 in TFA-d and diluting with THF-d8 (as opposed to 
mixing two solutions of CP1-pBA30).  
 
SANS analysis 
Models incorporated in the NCNR analysis macro using IGOR Pro 6.34A were used 
to fit to the collected data.[51] The general procedure followed for fitting was to begin with a 
uniform, monodisperse, hard sphere model, then, where necessary, fit complexity was 
increased to consider polydisperse spheres, uniform ellipsoids, uniform cylinders, 
polydisperse cylinders, and core-shell cylinders to gain further insight. The parameters: scale 
(volume fraction), solvent SLD and incoherent background were always fixed while the other 
parameters were fit to the data. Repeated fittings with various manually input starting 
parameters were used to assess the validity of the fit. Solvent SLDs were determined from 
literature values of scattering lengths and cross sections[52] using the NCNR SLD 
calculator,[53] and SLDs of solvent mixtures were determined by weighted averages. Where 
removed, incoherent scattering was subtracted using the Porod Law (I(q)·q4 vs q4 plot).[54] 
 
Static light scattering (SLS) 
SLS experiments were performed on an ALV-CGS3 goniometer system. A 633 nm, 
vertically polarised laser was used, and the sample was kept at 20 °C throughout the 
experiment. Dark count rate was recorded at 90°, distilled and filtered toluene (n = 1.491, 
Rθ = 1.35 × 10-5) was used to calibrate the instrument, and filtered THF (n = 1.409) was used 
as a blank for background subtraction. CP-(pBA33)2 in THF (2 mM) was prepared with 
filtered THF (but the sample was not filtered) and analysed in a quartz cell at angles 15°-149° 
taking 3×10 sec intensity measurements at 2° increments. 
 Results and Discussion 
A range of self-assembling cyclic peptides (CP1-3) containing azide moieties were 
obtained by Fmoc- solid phase peptide synthesis (SPPS) and poly n-butyl acrylates 
containing an alkyne functional group at the α-terminus were prepared using reversible 
addition-fragmentation chain transfer (RAFT) polymerisation. The peptide polymer 
conjugates were then prepared by reaction of minimal excess polymer, CPs and polymers in a 
microwave-assisted copper(I) catalysed azide-alkyne cycloaddition (CuAAC) using a high 
concentration of copper catalyst (Scheme 1), following a previously published procedure.[29] 
The cyclic peptides (CPs) and the cyclic-peptide polymer conjugates were then examined 
using SANS to determine the structure of the assemblies formed in solution. 
 
 
Scheme 1: Synthetic overview of cyclic peptides and (cyclic peptide)-polymer conjugates. 
 
Influence of polymer conjugation 
First we examined cyclo[(Lys(N3)-D-Leu-Trp-D-Leu-)2] CP1, which has two azide 
containing residues (incorporated to enable the introduction of two polymer chains with 
alkyne end groups). A very limited range of solvents can be used to obtain macroscopically 
clear solutions (i.e. submicron sizes) of unconjugated CP1, and trifluoroacetic acid (TFA) 
and dimethylsulfoxide (DMSO) are commonly used solvents to dissolve CPs containing these 
residues.[28,29,55-57] Small angle neutron scattering (SANS) enabled direct analysis of the 
macroscopically dissolved CP1 in TFA-d and DMSO-d6 (Figure 1). 
 
 
Figure 1: SANS data of CP1 in TFA-d and DMSO-d6. CP1 is molecularly dissolved in 
TFA-d but forms 1-15 nm structures in DMSO-d6. The figure shows the fit of a uniform 
ellipsoid model (disk-like) to CP1 in DMSO-d6 (4 mM). This has been interpreted as bundles 
of short tubes in DMSO-d6. See Figures S1-S3 for model fitting. 
 
In TFA-d, CP1 does not scatter above the background incoherent scattering from the 
solvent. This suggests that any structure in solution is smaller than 1 nm, corresponding to the 
molecular dissolution of CP1. On the other hand, CP1 in DMSO-d6 shows significant small-
angle scattering over the probed q-range, which increases with concentration, indicating the 
presence of small aggregates. These scattering functions were inconsistent with spherical 
aggregates, but could be adequately fit by models with disk-like geometry such as 
homogeneous oblate spheroids or cylinders. Best fit parameters are similar for the two 
models, yielding short cylinders with radii of 12±0.5 nm and lengths of 4.0 nm, or spheroids 
with large radii of 13±0.5 nm and short (axial) radii of 2.3 nm, very close to half the best-fit 
cylinder length. Including polydispersity into the cylinder radius improves the fit slightly but 
does not affect cylinder length (see Figures S1-S3 for further details).[51] These dimensions 
are larger than expected for a single CP1 nanotube (which would have a radius ~ 0.5 nm), but 
in line with earlier observations by Ghadiri et al. who observed electron (and optical) 
microscopy images of unconjugated CPs in bundles (microcrystals).[17,56,58] We interpret the 
SANS patterns to mean that CP1 exists as bundles of short tubes in DMSO-d6, a concept that 
has also been proposed in the study of CP ion channel mechanism.[59-61] Indeed, while early 
work in the field presented the mechanism of ion transport through the internal cavities of 
cyclic peptide nanotubes,[62,63] assembly into ‘barrel and stave’ structures has also been 
suggested.[64] Furthermore, the work of Ramesh et al. and Kodama et al. have shown that the 
transport of ions is possible with cyclic peptides with only 4 or 6 residues, for which the 
internal pore is too small to allow ion transport, thus suggesting a barrel and stave 
assembly.[59-61] 
Using microwave-assisted CuAAC, we conjugated CP1 with two chains of alkyne-
functionalised poly(n-butyl acrylate) (pBA30; Mn 4100 g.mol-1, Đ 1.16) yielding CP1-
(pBA30)2 (Scheme 1). We probed the effect of the solvent environment on the assembly of the 
(cyclic peptide)-polymer conjugates, using a variety of solvents and mixtures to empirically 
correlate the influence of the solvent H-bonding strength in competition with H-bonding 
between CPs, and the solvent quality towards the peptide and polymer. 
Remarkably, unlike CP1, the peptide-polymer conjugate CP1-(pBA30)2 in TFA-d 
shows an assembly of appreciable size by SANS (Figure 2). This is likely due to the polymer 
shielding the peptide from the TFA-d molecules, a phenomenon observed in a previous 
study.[43] This scattering pattern can also be fit to short cylinders. Here the best fit cylinder 
radius is 1.4 nm and length 6.5 nm (note, a fit to prolate ellipsoids gives comparable radii of 
1.5 nm and 4.2 nm, respectively, see Figures S4-S5). This cylinder radius is greater than 
expected for the cyclopeptide alone, but is consistent with expectations for an isolated CP 
nanotube surrounded by a polymer sheath swollen by solvent. More complex models, to 
account for a solvent-penetrable polymer shell, were not necessary to fit the data; however 
the obtained radii and scattering length densities (SLDs) must be interpreted as an average of 
the peptide core and solvated polymer shell. The fact that the obtained radius is only slightly 
larger than expected for a single, unconjugated cyclic peptide nanotube and does not account 
for the full length of the polymer chain, shows not only the low contrast of the polymer but is 
also evidence of isolated cyclic peptide nanotubes that are sterically stabilised by the polymer 
chains. These findings match previous SANS analyses performed on these systems.[43] 
CP1-(pBA30)2 was difficult to dissolve in DMSO-d6, and this is clearly seen in the q-4 
scattering behaviour in Figure 2 at low q (< 0.03 Å-1) corresponding to Porod scattering by 
large particles (> 100 nm).[65,66] This is consistent with the poor solubility of pBA in DMSO 
being carried over to the conjugate. However SANS reveals a coexistence of precipitate with 
a population of small, low aspect ratio aggregates in DMSO-d6, despite the incompatibility 
between DMSO-d6 and the pBA chains. These aggregates are comparable in their dimensions 
with those seen in TFA. A cylinder fit yields a radius of 1 nm and a length of 6 nm, (or radii 
of 1 nm and 4 nm for a prolate spheroid). Here also the assemblies are short, and consistent 
with isolated nanotubes sterically stabilised by the polymer conjugate, and very different 
from the cyclopeptide CP1 alone.  
 
 
Figure 2: SANS data of CP1-(pBA30)2 in TFA-d and DMSO-d6. CP1-(pBA30)2 exists as 
short individual tubes. Precipitation is observed for the conjugate in DMSO-d6. See Figures 
S4-S5 for model fitting. 
 
Influence of solvent 
Since the conjugation of a polymer provides solvent solubility to the nanotubes, the 
conjugate CP1-(pBA30)2 was dissolved in tetrahydrofuran-d8 (THF-d8) and chloroform-d 
(CDCl3). In these less competitive solvents, H-bonding between CPs is promoted, and the 
SANS patterns exhibit a q-1 power law of over a wide q-range (Figure 3), characteristic of 
long rigid rods. This observation is consistent with previously reported electron microscopy 
imaging of chemically locked-in CP-polymer conjugates.[39,43] With no Guinier regime in the 
available q range, fitting the data gave cylinders with very high aspect ratios, with a lower 
bound on the average length >110 nm, and a cylinder radius of ~ 1 nm in both solvents 
(Figure S6). Even at very low q (0.001 Å-1) the q-1 behaviour persists in the scattering data 
(Figure 4) showing the rods to be extremely long and rigid, raising the minimum observed 
length of the assembly to 1700 nm. Such long assemblies support the notion of a cooperative 
assembly mechanism,[67] which has been suggested to originate from the stabilisation of 
multiple bonds and peptide backbone conformation.[56,68] The number- and weight- average 
degree of polymerisation, DP # and DP $ respectively, of a supramolecular assembly with 
a single nucleation step can be described by:[69] 
 
 DP # = 𝜎 + (1 − 𝜎)(1 − 𝐾 A ).𝜎 1 − 𝐾 A + (1 − 𝜎)(1 − 𝐾 A ). (1) 
 DP $ = 𝜎 1 + 𝐾 A + (1 − 𝜎)(1 − 𝐾 A )/𝜎 1 − 𝐾 A + (1 − 𝜎)(1 − 𝐾 A )/ (2) 
 
Where σ = K2/K; [A] is the concentration of unassembled monomer, K2 is the equilibrium 
constant for the dimerization of two monomers, and K is the equilibrium constant for the 
addition of one monomer to an assembly with two units or more. Based on thermodynamic 
studies of partially N-methylated CPs (monotopic species), the highest equilibrium constants 
for the formation of dimers have been found to be in the order of 2000 M-1 in CDCl3.[70] For 
an isodesmic supramolecular polymerisation (i.e. K2 = K) with association constant 
K ~ 2000 M-1 at 1 mM, we calculate a weight average degree of polymerisation <DP>w ~ 3 
(length ~ 1.5 nm†).[69] This is significantly shorter than the assembly observed by SANS; in 
fact, K ~ 107 M-1 is required to explain the observed minimum length through an isodesmic 
growth mechanism. If we however assume a cooperative growth mechanism (in the simplest 
case of a nucleation step at two units, i.e. K2 < K) and an association constant for the first two 
units of the assembly K2 ~ 2000 M-1, then to obtain a <DP>w ~ 220 (length ~ 110 nm†) we 
can estimate the equilibrium constant for subsequent growth K to be greater than 200 000 M-1 
in CDCl3 (Figure 5). If we consider longer assemblies (length ~ 1700 nm, <DP>w ~ 3400†) 
such as those observed in THF, and with the continued assumption of K2 ~ 2000 M-1, then we 
estimate K ~ 1 200 000 M-1 (Figure 5).  
 
                                                
† A length of 5 Å per unit[17] has been used to estimate the length of assembly from DP. 
 
Figure 3: SANS data of CP1-(pBA30)2 in CDCl3 and THF-d8. Conjugate exists as long and 
individual tubes. See Figure S6 for model fitting. 
 
 
 (a) SANS only (b) SANS and SLS overlayed 
Scale 0.019†	 0.019†	
Radius (Å) 8.87	 9.10	
Length (Å) >2100	 >17000	
SLD cylinder (×10-6 Å-2) 2.70	 2.80	
SLD solvent (×10-6 Å-2) 6.35†	 6.35†	
Figure 4: Uniform cylinder model fits to SANS data of (a) CP1-(pBA30)2 in THF-d8 (2 mM); 
and (b) CP-(pBA33)2 in THF (2 mM). Incoherent background scattering has been subtracted. 
SLS data has been offset to match the SANS data. (†=held parameter value) 
 
 
Figure 5: Calculated number- and weight-average degree of polymerisation <DP>n and 
<DP>w versus total concentration of CP units for isodesmic (blue lines) and cooperative 
growth mechanisms, with s = 0.01 (red lines) and s = 0.0016 (black lines).[69] A cooperative 
growth mechanism is used to explain the long assembly. 
 
To probe solvent conditions with properties between those of TFA and THF or 
CDCl3, solvent mixtures of TFA-d/THF-d8 and TFA-d/CDCl3 were used. Table 1 shows the 
results of these experiments (see Figures S4-9 for scattering profiles and model fitting). With 
only 10 vol% TFA-d, the assemblies are found to be significantly shorter than those observed 
in either neat THF-d8 or CDCl3 and yield comparable dimensions to our previous findings 
with the same solvent composition.[43] A closer look at the fitted parameters for radius and 
contrast of CP1-(pBA30)2 in the pure solvents suggests that the polymer chains are better 
solvated in CDCl3 (larger radius and lower contrast against solvent) than in THF-d8 (smaller 
radius and higher contrast). Note that this comparison was made by fixing the scale, for the 
fitting, according to the volume fraction of each sample. As a cooperative system with the 
observed lengths, it is reasonable to assume that the entire sample is contributing to the 
scattering (as the unassembled species is at least 3 orders of magnitude lower than the total 
concentration). The difference in solvation means that TFA can more easily access the CP 
and disrupt its stacking when mixed with CDCl3 than THF-d8, which explains the observed 
differences in assembly lengths between TFA-d/THF-d8 (1:9 v/v) and TFA-d/CDCl3 
(1:9 v/v). To probe this, CP1-(pBA30)2 was dissolved first into TFA-d, then diluted with 
THF-d8 to a final concentration and solvent mixture of TFA-d/THF-d8 (10 vol%). In this case 
even shorter tubes were observed, leading to the conclusion that a non-thermodynamic 
product is formed in one or other addition sequence (Figure S9). The details of this require 
further study, but do suggest the potential for obtaining kinetic products in order to access a 
wider range of structures.[71,72] 
 
Table 1: Length parameter from fitting uniform cylinder model to scattering profiles of 
CP1-(pBA30)2 at 1 mM in various solvent mixtures. See Figures S4-9 for scattering profiles 
and model fitting. 
Composition of TFA-d (vol%) 100 90 10 0 
Length in TFA-d/THF-d8 (nm) 10 10 30 >110 
Length in TFA-d/CDCl3 (nm) 10 10 10 >110 
 
Influence of cyclic peptide side-chain functionality 
A key feature of using self-assembling cyclic peptides is their versatility in chemical 
functionality by the inclusion of residues with various functional groups. Here we use CP2, 
which substitutes (from CP1) the two Trp residues for two Lys(Boc) residues, as a model 
compound that might be potentially used to functionalise the immediate shell of a tube (i.e. 
conjugated to the peptide and not the polymer). Attempts to conjugate pBA30 to CP2 by 
microwave-assisted CuAAC resulted in conversion < 100 % as judged by ATR-FTIR (Figure 
S10). We attribute this difference in conjugation efficiency to the bulky Boc protecting 
groups which reduce the accessibility of the sites (based on our findings of attempting to 
conjugate 4 polymers to a CP with 4 azide sites).[29] Conjugation efficiency of pBA30 to Boc-
deprotected CP2, i.e. CP3, was difficult to ascertain due to the relative insolubility of CP3 
which biased the observation of the conjugate. Our uncertainty with conversion led us to 
synthesise samples where the cyclic peptide was in excess over the polymer during 
conjugation, to determine whether a higher number of unconjugated sites would impact the 
assembly. Conjugates CP2-(pBA30)2, CP2-(pBA30)1.5 (2.1 eq and 1.5 eq of polymer used, 
respectively) and CP3-(pBA30)2, CP3-(pBA30)1.5 (2.1 eq and 1.5 eq of polymer used, 
respectively) in CDCl3 were examined by SANS to assess the impact of changing residue 
function on the CP assembly (Figure 6). It is clear from the scattering profiles that the 
structures of these two conjugates differ from the CP1 based conjugates. The scattering 
patterns are all consistent with extended, anisotropic structures, and can all be fit 
satisfactorily by rigid rod models (Figure 6). At wavevectors (q < 0.03 Å-1), CP2-based 
conjugates show a trend towards the expected q-1 power law of rigid rods (see Figure S11 for 
model fitting), but the steep region indicates much larger cylinder radii than CP1-derived 
aggregates. This has been modelled by including polydispersity in the radial component via a 
Schultz distribution with a fitted polydispersity of ca. 1.0 (see Figure S12 for model fitting). 
We interpret this to be a result of the incomplete conjugation and the consequent tendency of 
the tubes to partially bundle. This value of radial polydispersity is reasonable as the 
aggregation of even two tubes will be statistically significant when compared to an isolated 
nanotube. 
The scattering patterns of CP3 conjugates at both grafting densities are similar to 
CP1-(pBA30)2 in the intermediate q range, which indicates the presence of isolated cylinders. 
However a transition to Porod scattering is seen at lower q, indicative of large particles or 
precipitates.[65,66] This could be the result of the use and incompatibility of CDCl3 as the 
solvent and the polar nature of the lysine residues in the CP3 conjugates. Also of note, in 
both CP2 and CP3 conjugates, the difference between using 2.1 and 1.5 equivalents of 
polymer per CP during the conjugation reaction has a minimal impact on the final assembly. 
For conjugations involving CP2, this suggests a maximum grafting efficiency of 1.5 
polymers per CP. 
 
 
Figure 6: SANS data of CP1-(pBA30)2, CP2-(pBA30)2, CP2-(pBA30)1.5, CP3-(pBA30)2, 
CP3-(pBA30)1.5, in CDCl3. Variation of peptide and variation of polymer equivalents used 
during conjugation. See Figure S11-S12 for model fitting. 
 
Conclusion 
We have shown the direct characterisation of nanotube forming (cyclic peptide)-
polymer conjugates in a variety of conditions. These conditions and self-assembly products 
have been summarised in Scheme 2. Fitting the form factor with cylindrical models suggests 
the attachment of pBA can sterically stabilise these assemblies, preventing the formation of 
bundles as otherwise observed in the assembly of the unconjugated cyclic peptide in DMSO-
d6. Interestingly, in the case of the conjugate in DMSO-d6, large structures were also 
observed to coexist with isolated nanotubes; this complex behaviour is likely to be related to 
the incompatibility (i.e. low solubility) of pBA with DMSO. In TFA-d, where there was no 
assembly of the unconjugated cyclic peptide, the polymer promoted the formation of (short) 
nanotubes in the conjugate, a phenomenon we have attributed to the polymer chains shielding 
the solvent from the CP hydrogen bond donors and acceptors. This notion was further 
explored by using solvent mixtures varying in their ability to compete with the H-bonding 
between CPs. It was found that 10 vol% TFA-d was enough to significantly shorten the 
length of the assembly from a non-polar solvent. CP-pBA conjugates in THF were found to 
exist as individual and long (> 1700 nm) nanotubes; which, by extension of the observed 
length and concentration, suggests a strongly cooperative system where we estimate for 
nucleation K2 = 2000 M-1, and for elongation K > 1 200 000 M-1 as a minimum for 
cooperative growth to explain the observations. We explored the variation of residues of the 
CP from Trp to Lys(Boc) or Lys, where an observable difference was found between the 
resulting self-assembled structure for each of these species. Specifically, the incomplete 
conjugation due to Lys(Boc) residues led to partial lateral aggregation; in the case of Lys 
residues, while unbundled nanotubes were observed, aggregates were also present in CDCl3 
which have been attributed to the polar nature of the Lys residues. 
 
 
Scheme 2: Simplified summary depicting: (a) self-assembling units, (b) key assembly 
conditions, and (c) products of self-assembly with short descriptions below. Length scales 
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